2. Anti-infection
  3. Fungal
  4. CHNQD-02204

CHNQD-02204 is a potent and selective antifungal agent with in vitro activity against Candida albicans, with a MIC of 0.025 μg/mL. CHNQD-02204 inhibits ergosterol biosynthesis, disrupts the membrane integrity and biofilm formation of Candida albicans, and suppresses the morphological transition of Candida albicans from yeast to hyphal form. CHNQD-02204 can be used in studies related to candidal infections.

For research use only. We do not sell to patients.

CHNQD-02204

CHNQD-02204 Chemical Structure

CAS No. : 3094676-22-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CHNQD-02204 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CHNQD-02204 is a potent and selective antifungal agent with in vitro activity against Candida albicans, with a MIC of 0.025 μg/mL. CHNQD-02204 inhibits ergosterol biosynthesis, disrupts the membrane integrity and biofilm formation of Candida albicans, and suppresses the morphological transition of Candida albicans from yeast to hyphal form. CHNQD-02204 can be used in studies related to candidal infections[1].

In Vitro

CHNQD-02204 (0.05 μg/mL; 2 h) disrupts the cell surface integrity of Candida albicans ATCC 10231, leading to cell shrinkage and indentation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CHNQD-02204 Related Antibodies
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUC0-t AUC0-∞ CL
Rat[1] 2.5 mg/kg i.v. 12.7 min 1 min 5952.5 ng/mL 31896.7 min·ng/mL 46463.1 min·ng/mL 53.8 mL/min/kg
In Vivo

CHNQD-02204 (2.5 mg/kg; intravenous injection; administered 3 times) reduces the fungal burden in the spleen, lung and kidney of immunocompromised mice with candidiasis[1].
CHNQD-02204 (2.5 mg/kg; intravenous injection; twice daily; for 3 consecutive days) reduces the fungal burden in the spleen, lung and kidney of immunocompromised mice with disseminated candidiasis, and alleviates infection-induced body weight loss[1].
CHNQD-02204 (10 mg/kg; intravenous injection; single administration) is well tolerated in healthy female C57BL/6J mice, with no mortality, body weight changes or histopathological abnormalities observed within 7 days[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ICR (female, 6-week-old, 24-26 g, immunocompromised via intraperitoneal cyclophosphamide injection)[1]
Dosage: 2.5 mg/kg
Administration: i.v.; three doses at 2, 6, and 10 h post-infection
Result: Reduced fungal burden in the spleen by 0.40 log10 CFU compared with the infected control group.
Reduced fungal burden in the lung by 0.29 log10 CFU compared with the infected control group.
Reduced fungal burden in the kidney by 0.62 log10 CFU compared with the infected control group.
Animal Model: ICR (female, 6-week-old, 24-26 g, immunocompromised via intraperitoneal cyclophosphamide injection)[1]
Dosage: 2.5 mg/kg
Administration: i.v.; twice daily; 3 consecutive days
Result: Reduced fungal burden in the spleen by 0.37 log10 CFU compared with the infected control group.
Reduced fungal burden in the lung by 0.78 log10 CFU compared with the infected control group.
Reduced fungal burden in the kidney by 0.41 log10 CFU compared with the infected control group.
Marked reduction of fungal content in multiple organs, with almost no fungal growth observed in the lungs via periodic acid-Schiff staining.
Mitigated weight loss induced by fungal infection during the 3-day treatment period.
Molecular Weight

517.31

Formula

C25H18Cl2O8
CAS No.
SMILES

ClC(C=CC=C1)=C1C(OC2=C(Cl)C=CC=C2C3=C(OC)C(C4=C(O)C=C(OC)C(OC)=C4O3)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CHNQD-02204 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CHNQD-022043094676-22-6CHNQD02204CHNQD 02204FungalAspergillus candidusyeast-to-hypha morphological transitionsystemic candidiasisCandida albicansergosterolaspergillus fumigatus infectionmurine modelbiofilm formationC57BL/6J micecell membrane integrityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CHNQD-02204
Cat. No.:
HY-183333
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.